SCHEDULE: Lyell Immunopharma: Key Investor Reduces Stake Below 5%

Newton (PTC) Limited and affiliated entities have reduced their beneficial ownership in Lyell Immunopharma, Inc. to 3.93%.

Summary

• Newton (PTC) Limited, Orland Properties Limited, Gemini GP Limited, and Gemini Investments, L.P. collectively reported beneficial ownership of 754,698 shares of Lyell Immunopharma, Inc. common stock.
• This represents 3.93% of the company's outstanding common stock.
• The ownership percentage is based on 19,211,202 shares of common stock outstanding as of August 7, 2025, as reported by the Issuer in its 10-Q filed on August 12, 2025.
• The event triggering this Schedule 13G amendment, indicating a change in ownership, occurred on September 30, 2025.
• Newton (PTC) Limited wholly owns Orland Properties Limited, which in turn wholly owns Gemini GP Limited, the general partner of Gemini Investments, L.P.; all are deemed to beneficially own the same shares.

Sentiment

Score: 4

Explanation: The reduction of a significant institutional stake below 5% is generally a negative signal, indicating reduced conviction or a strategic divestment, which could pressure the stock price.

Negatives

• A significant institutional investor group has reduced its stake in Lyell Immunopharma, Inc. to below the 5% threshold, potentially signaling a decreased conviction in the stock or a reallocation of capital.

Risks

• The reduction in beneficial ownership by a significant investor group could be perceived negatively by the market, potentially impacting investor confidence and share price.

Industry Context

This filing is a routine disclosure of a change in beneficial ownership by an institutional investor group. It does not provide specific industry context but reflects an investment decision within the biotechnology or pharmaceutical sector where Lyell Immunopharma operates.

Stakeholder Impact

• Shareholders may interpret the reduction in stake by a significant investor as a negative signal, potentially leading to decreased confidence and downward pressure on the stock price.

Key Dates

Recommendation

While the reduction in a significant institutional stake is a negative data point, a Schedule 13G filing alone does not provide enough fundamental information about the company's operations, financials, or future prospects to warrant a 'sell' or 'strong sell' recommendation. It suggests caution and warrants further investigation into the company's performance and other market factors. A 'hold' recommendation is appropriate, advising investors to monitor the situation and await more comprehensive financial updates.

Keywords

Lyell Immunopharma, LYEL, Schedule 13G, beneficial ownership, institutional investor, stake reduction, common stock, Newton PTC Limited, Gemini Investments